The predictive value of urinary albumin-to-creatinine ratio for coronary artery abnormalities in Kawasaki disease

尿白蛋白/肌酐比值对川崎病冠状动脉异常的预测价值

阅读:3

Abstract

BACKGROUND: To explore the application value of the urinary albumin-to-creatinine ratio (UACR) in the predictive of coronary artery (CA) abnormalities in Kawasaki disease (KD) during acute phase. METHODS: This retrospective study included 109 KD patients who were stratified into CA abnormalities and normal CA groups based on echocardiography at one month after KD onset. Clinical, demographic, and laboratory data were analyzed. Urinary microalbumin and urinary creatinine values were collected during the acute phase before high-dose intravenous immunoglobulin (IVIG) therapy, and UACR was calculated. RESULTS: The 109 patients consisted of 70 males and 39 females. The orrelation analysis revealed no significant associations between UMA and serum albumin (Alb) (r = -0.073, p = 0.449), or between UACR and serum Alb (r = -0.128, p = 0.186) in KD patients. Among the 109 patients, 23 (21.1%) developed CA abnormalities. The levels of UACR, CRP, ALT and NT-proBNP were significantly elevated in the CA abnormalities group compared to the normal CA group, while serum Alb and prealbumin (PA) were decreased (p < 0.05). Multivariate binary logistic regression analysis identified elevated UACR and reduced serum Alb levels as independent predictors of CA abnormalities (p < 0.05). The optimal cutoff values for UACR and serum Alb were 24.1 mg/g and 37.75 g/L, respectively. Combined UACR and serum Alb, the predictive performance improved, with an area under the curve (AUC) of 0.904 (95% CI: 0.848-0.961), a sensitivity of 91.3%, and a specificity of 81.4%. CONCLUSIONS: UACR and serum Alb, assessed during the acute phase of KD, could serve as early biomarkers for CA abnormalities, particularly when analyzed in combination.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。